Logo image of CLXT

CALYXT INC (CLXT) Stock Fundamental Analysis

NASDAQ:CLXT - Nasdaq - US13173L2060 - Common Stock - Currency: USD

6.3  +0.33 (+5.53%)

After market: 6.99 +0.69 (+10.95%)

Fundamental Rating

2

Overall CLXT gets a fundamental rating of 2 out of 10. We evaluated CLXT against 572 industry peers in the Biotechnology industry. While CLXT seems to be doing ok healthwise, there are quite some concerns on its profitability. CLXT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CLXT had negative earnings in the past year.
In the past year CLXT has reported a negative cash flow from operations.
CLXT had negative earnings in each of the past 5 years.
CLXT had a negative operating cash flow in each of the past 5 years.
CLXT Yearly Net Income VS EBIT VS OCF VS FCFCLXT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M -40M

1.2 Ratios

CLXT has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CLXT Yearly ROA, ROE, ROICCLXT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -50 -100 -150 -200

1.3 Margins

With an excellent Gross Margin value of 100.00%, CLXT belongs to the best of the industry, outperforming 99.36% of the companies in the same industry.
CLXT's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for CLXT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 100%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y0%
CLXT Yearly Profit, Operating, Gross MarginsCLXT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -5K -10K

More info and screens

4

2. Health

2.1 Basic Checks

CLXT does not have a ROIC to compare to the WACC, probably because it is not profitable.
CLXT has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, CLXT has an improved debt to assets ratio.
CLXT Yearly Shares OutstandingCLXT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
CLXT Yearly Total Debt VS Total AssetsCLXT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -17.41, we must say that CLXT is in the distress zone and has some risk of bankruptcy.
CLXT's Altman-Z score of -17.41 is on the low side compared to the rest of the industry. CLXT is outperformed by 84.16% of its industry peers.
CLXT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -17.41
ROIC/WACCN/A
WACC7.68%
CLXT Yearly LT Debt VS Equity VS FCFCLXT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

A Current Ratio of 0.61 indicates that CLXT may have some problems paying its short term obligations.
CLXT has a Current ratio of 0.61. This is amonst the worse of the industry: CLXT underperforms 91.68% of its industry peers.
A Quick Ratio of 0.61 indicates that CLXT may have some problems paying its short term obligations.
CLXT has a worse Quick ratio (0.61) than 91.52% of its industry peers.
Industry RankSector Rank
Current Ratio 0.61
Quick Ratio 0.61
CLXT Yearly Current Assets VS Current LiabilitesCLXT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for CLXT have decreased strongly by -289.74% in the last year.
The Revenue for CLXT has decreased by -99.23% in the past year. This is quite bad
The Revenue for CLXT have been decreasing by -20.99% on average. This is quite bad
EPS 1Y (TTM)-289.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-678.57%
Revenue 1Y (TTM)-99.23%
Revenue growth 3Y-72.19%
Revenue growth 5Y-20.99%
Sales Q2Q%31.25%

3.2 Future

CLXT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.45% yearly.
The Revenue is expected to grow by 138.26% on average over the next years. This is a very strong growth
EPS Next Y82.92%
EPS Next 2Y36.68%
EPS Next 3Y22.73%
EPS Next 5Y16.45%
Revenue Next Year38.59%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y138.26%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CLXT Yearly Revenue VS EstimatesCLXT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
CLXT Yearly EPS VS EstimatesCLXT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CLXT. In the last year negative earnings were reported.
Also next year CLXT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLXT Price Earnings VS Forward Price EarningsCLXT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLXT Per share dataCLXT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as CLXT's earnings are expected to grow with 22.73% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.68%
EPS Next 3Y22.73%

More info and screens

0

5. Dividend

5.1 Amount

CLXT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CALYXT INC

NASDAQ:CLXT (5/31/2023, 8:09:09 PM)

After market: 6.99 +0.69 (+10.95%)

6.3

+0.33 (+5.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2023-05-01/amc
Earnings (Next)08-02 2023-08-02/amc
Inst Owners0.01%
Inst Owner Change0%
Ins Owners507.02%
Ins Owner Change0%
Market Cap31.33M
Analysts47.5
Price Target36.98 (486.98%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.79%
Min EPS beat(2)-78.1%
Max EPS beat(2)46.52%
EPS beat(4)3
Avg EPS beat(4)10.8%
Min EPS beat(4)-78.1%
Max EPS beat(4)63.69%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-79%
Min Revenue beat(2)-99.18%
Max Revenue beat(2)-58.82%
Revenue beat(4)0
Avg Revenue beat(4)-78.68%
Min Revenue beat(4)-99.18%
Max Revenue beat(4)-58.82%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)400%
PT rev (3m)4900%
EPS NQ rev (1m)-900%
EPS NQ rev (3m)-5.26%
EPS NY rev (1m)0%
EPS NY rev (3m)74.91%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-79.84%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 187.63
P/FCF N/A
P/OCF N/A
P/B 11.75
P/tB 11.75
EV/EBITDA N/A
EPS(TTM)-3.04
EYN/A
EPS(NY)-0.28
Fwd EYN/A
FCF(TTM)-3.28
FCFYN/A
OCF(TTM)-3.08
OCFYN/A
SpS0.03
BVpS0.54
TBVpS0.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 100%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y0%
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 59.09%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.61
Quick Ratio 0.61
Altman-Z -17.41
F-Score3
WACC7.68%
ROIC/WACCN/A
Cap/Depr(3y)72.02%
Cap/Depr(5y)114.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-289.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-678.57%
EPS Next Y82.92%
EPS Next 2Y36.68%
EPS Next 3Y22.73%
EPS Next 5Y16.45%
Revenue 1Y (TTM)-99.23%
Revenue growth 3Y-72.19%
Revenue growth 5Y-20.99%
Sales Q2Q%31.25%
Revenue Next Year38.59%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y138.26%
EBIT growth 1Y19.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year86.66%
EBIT Next 3Y23.13%
EBIT Next 5Y17.49%
FCF growth 1Y61.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y62.46%
OCF growth 3YN/A
OCF growth 5YN/A